von Tresckow Bastian, Diehl Volker
University Hospital of Cologne, Department I of Internal Medicine , Kerpener Str. 62, 50937 Cologne , Germany +49 221 478 97657 ; +49 221 478 98622 ;
Expert Opin Emerg Drugs. 2014 Jun;19(2):215-24. doi: 10.1517/14728214.2014.912277. Epub 2014 Apr 21.
Most patients with Hodgkin lymphoma (HL) are cured with modern combined modality first-line treatments. Even ~ 50% of patients with relapsed/refractory HL can be cured with high-dose chemotherapy (HDCT) and autologous stem cell transplantation. However, chemotherapy and radiotherapy cause significant acute and long-term side effects and patients relapsing after HDCT have a dismal prognosis. New drugs are therefore needed to reduce the toxicity of first-line treatments and to increase the efficacy of relapse treatments. Moreover, new drugs are needed for the treatment of older patients with HL because results with current treatments are disappointing.
This article discusses promising new drugs for the treatment of classical HL that have been evaluated in the last years. There is a focus on the antibody drug conjugate brentuximab vedotin and its potential for the future treatment of HL. Moreover, data on the histone deacetylase inhibitors panobinostat and mocetinostat, the mammalian target of rapamycin inhibitor everolimus, the Janus kinase 2 inhibitor SB1518 and the immunomodulatory agent lenalidomide are summarized.
Besides improving the prognosis of relapsed patients, new drugs should be used to replace the most toxic compounds in first-line therapy to reduce acute and long-term toxicities of the treatment.
大多数霍奇金淋巴瘤（HL）患者可通过现代联合一线治疗治愈。即使约50%复发/难治性HL患者也可通过高剂量化疗（HDCT）和自体干细胞移植治愈。然而，化疗和放疗会导致显著的急性和长期副作用，且HDCT后复发的患者预后不佳。因此，需要新型药物来降低一线治疗的毒性并提高复发治疗的疗效。此外，由于目前治疗HL老年患者的效果令人失望，也需要新型药物来治疗此类患者。
本文讨论了近年来已评估的用于治疗经典HL的有前景的新型药物。重点关注抗体药物偶联物本妥昔单抗及其在HL未来治疗中的潜力。此外，还总结了组蛋白去乙酰化酶抑制剂帕比司他和莫西司他、雷帕霉素靶蛋白抑制剂依维莫司、Janus激酶2抑制剂SB1518以及免疫调节剂来那度胺的数据。
除改善复发患者的预后外，新型药物还应用于替代一线治疗中毒性最强的化合物，以降低治疗的急性和长期毒性。
